Potassium Bromate vs Olestra: which is worse?

What is Potassium Bromate?

Potassium bromate (KBrO3) is an oxidizing agent used in commercial bread baking as a flour maturing agent and dough conditioner. It strengthens gluten networks, improves dough elasticity, and produces a more uniform, light-textured baked product. It is a white crystalline powder.

What is Olestra?

Olestra (brand name Olean) is a synthetic fat substitute made from sucrose and fatty acids. Unlike regular fats, olestra is not absorbed by the digestive system — it passes through the body unchanged, providing zero calories while mimicking fat's texture and taste in food. It was developed by Procter & Gamble and FDA-approved in 1996.

Documented risks

Potassium Bromate: Potassium bromate is classified by the International Agency for Research on Cancer (IARC) as Group 2B — a possible human carcinogen — based on sufficient evidence in animals. This classification was formalized in 1999. The landmark toxicology study is Kurokawa et al. (1990), published in Environmental Health Perspectives (PMC1567851), which demonstrated that KBrO3 induces renal cell tumors (kidney cancer), mesotheliomas of the peritoneum, and follicular cell tumors of the thyroid in rats. Importantly, the researchers demonstrated KBrO3 is a complete carcinogen — it possesses both tumor-initiating and tumor-promoting activities for renal tumorigenesis. The mechanism of carcinogenicity involves generation of reactive oxygen species, particularly hydroxyl radicals and superoxide radicals. These radicals cause oxidative DNA damage, specifically 8-hydroxydeoxyguanosine (8-OHdG) formation in rat kidney cells — a well-characterized biomarker of oxidative DNA damage. California declared potassium bromate a known carcinogen under Proposition 65 in 1991, requiring cancer warning labels on California products containing it. Multiple advocacy organizations including CSPI (1999 petition) and EWG (2015 petition) have petitioned the FDA for a federal ban. As of 2025, the FDA has urged voluntary industry elimination since the early 1990s but has not issued a formal ban. Nephrotoxicity from high-dose potassium bromate is well documented in case reports of accidental or intentional poisonings: it causes irreversible renal tubular necrosis, permanent deafness (cochlear damage), and blindness (optic nerve damage). These effects occur at doses far above food consumption scenarios but demonstrate the compound's acute toxicological potency. FDA testing in 1999 found residual potassium bromate above expert-recommended safe limits in more than half of 17 tested bread and roll products, demonstrating that the 'it bakes off completely' argument does not always hold in commercial practice.

Olestra: Olestra caused significant gastrointestinal side effects that were prominently noted on mandatory warning labels: 'This Product Contains Olestra. Olestra may cause abdominal cramping and loose stools. Olestra inhibits the absorption of some vitamins and other nutrients. Vitamins A, D, E, and K have been added.' Reported gastrointestinal effects included diarrhea, abdominal cramping, oily anal leakage ('anal leakage' or 'rectal leakage'), and fatty stools. These effects were often embarrassing and uncomfortable. Multiple consumer complaints documented GI distress from Olean chips. Beyond GI effects, olestra significantly inhibits the absorption of fat-soluble vitamins (A, D, E, K) and fat-soluble carotenoids (lycopene, lutein, beta-carotene). Since fat-soluble vitamins require fat for absorption, and olestra passes through without being absorbed, it 'captures' these vitamins and carries them out of the body. Studies found olestra consumption reduced serum carotenoid levels, prompting Frito-Lay to fortify olestra products with fat-soluble vitamins to compensate. The FDA removed the mandatory GI warning requirement in 2003 after Frito-Lay argued the warning was overstated, though olestra's use had already declined dramatically due to consumer avoidance.